Actively Recruiting
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-04-20
300
Participants Needed
2
Research Sites
141 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
CONDITIONS
Official Title
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subject voluntarily agrees to participate and has signed the informed consent form.
- Has measurable disease according to RECIST v1.1 criteria.
- Has an Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of 12 weeks or more.
You will not qualify if you...
- Has symptomatic, untreated, or active central nervous system metastases.
- Has uncontrolled or severe cardiovascular disease.
- Has any active autoimmune disease or a history of autoimmune disease.
- Has active hepatitis B or hepatitis C infection.
- Has severe infections before starting the study treatment.
- Has active tuberculosis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
2
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Actively Recruiting
Research Team
Y
Yuanchao Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here